This species has a reputation for being bad-tempered and quick to strike. In northern
Malaysia it is responsible for some 700 incidents of
snakebite annually with a mortality rate of about 2 percent. Remarkably sedentary, it has often been found in the same spot several hours after an incident involving humans. There were only two deaths (related to intracerebral hemorrhage) and no amputations. The antivenin manufactured in Thailand seemed effective in reversing the blood clotting caused by the venom. Most patients remained stable and did not require antivenin. The authors suggested that victims not use traditional healers and avoid overuse of tourniquets. In a prospective phase of the study, bites occurred throughout the year but mostly early in the monsoon season (May and June). The venom acts, at least in part, by binding to and activating the
C-type lectin domain family 1 member B protein (also termed the CLEC1B or CLEC2 protein) on platelets. PDPN is a protein in humans that also binds to CLEC18 and like Calloselasma venom causes extensive thromboses reactions.
Venom and thrombosis treatment The venom of this species is used to isolate a thrombin-like enzyme called ancrod. This enzyme is used clinically to break down and dissolve
thrombi (blood clots) in patients and lower
blood viscosity to help prevent
heart attack and
stroke. ==References==